SGLT2 inhibitor safety study for type 1 diabetes
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This study tests whether a medication called an SGLT2 inhibitor is safe for people with type 1 diabetes. It aims to lower blood sugar without increasing the risk of dangerous complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be over 18 years old.
- You must have had type 1 diabetes for at least one year.
- You must be on a stable insulin regimen for at least 8 weeks before starting.
- You must use a continuous glucose monitor (CGM).
- Your kidney function must be at least 60% of normal (eGFR ≥60).
- Your hemoglobin A1c (average blood sugar over 3 months) must be 10% or less.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether using a dual continuous glucose and ketone monitor can help people with type 1 diabetes safely take a class of drugs called SGLT2 inhibitors, which may improve blood sugar control but can increase the risk of diabetic ketoacidosis (DKA). By closely monitoring changes in glucose and ketone levels, the study aims to prevent dangerous episodes while benefiting from the drug's effects.
This study tests different ways to monitor ketones (substances that can build up dangerously when your body lacks insulin) to lower the risk of diabetic ketoacidosis (DKA) in people with type 1 diabetes who also take SGLT-2 inhibitors (a type of diabetes drug). You'll wear a small sensor and follow a meal plan with carbs.
This trial tests how stopping a type 2 diabetes medication called an SGLT2 inhibitor affects the liver's production of sugar and ketones. It may help understand better ways to manage diabetes.
This study looks at how stopping a common diabetes drug (SGLT2 inhibitor) affects the body's risk of a serious condition called ketoacidosis. It may help understand who is most at risk and how to prevent it.
This trial tests how two diabetes medications, SGLT2i and pioglitazone, affect ketone production in people with type 1 diabetes. It aims to find new ways to improve blood sugar control.
This study tests whether a daily medication can slow down kidney damage in people with type 1 diabetes who already have some kidney problems. It may help protect your kidneys from getting worse.
Hear when a new Type 1 Diabetes (T1D) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.